%0 Journal Article
%T Case Commentary: Extending our therapeutic range against multidrug-resistant Candida.
%A Adelman MW
%A Andes DR
%J Antimicrob Agents Chemother
%V 68
%N 8
%D 2024 Aug 7
%M 39037274
%F 5.938
%R 10.1128/aac.00847-24
%X Deep-seated Candida spp. infections may necessitate extended durations of antifungal therapy. Increasing resistance to first-line antifungals threatens the most common options for long-term treatment. In this issue, Ponta et al. (Antimicrob Agents Chemother 68:e00750-24, 2024, https://doi.org/10.1128/aac.00750-24) present cases in which they used rezafungin, a novel long-acting echinocandin antifungal, for extended durations. While excellent clinical evidence supports the short-term safety of rezafungin, these cases demonstrate that rezafungin may additionally have a role in long-term suppressive therapy for antifungal-resistant Candida spp. infections.